More sarcoma patients are beating the odds with pembrolizumab! This immunotherapy can change the treatment for limb sarcomas ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

About the IOB-013/KN-D18 Pivotal Phase 3 Clinical Trial IOB-013/KN-D18 (Clinical Trials.gov: NCT05155254) is an open label, randomized Phase 3 pivotal clinical trial evaluating IO102-IO103 in ...

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...

“We have already adopted the strategy of a checkpoint inhibitor [pembrolizumab] after chemoradiation for stage ... tertiary ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Adding pembrolizumab to adjuvant chemotherapy in the first-line setting improved disease-free survival (DFS) in patients with high-risk endometrial cancer who have mismatch repair–deficient ...

Today's label printers range from small desktop units for file-folder paper labels to industrial-grade ones for labeling cables with plastic strips. Here's how to pick the right labeler ...

Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer. Ivonescimab reduced the risk of ...

"PD-1 inhibitors have truly been a game changer in classic Hodgkin lymphoma. Pembrolizumab and nivolumab [marketed as Keytruda and Opdivo] are currently being employed routinely in the relapsed and ...

The WHO’s guidance recommends governments implement “interpretive” labels that include nutritional information and some explanation of what that means about the healthiness of a product.